

**PROFESSOR WOLF HERVÉ FRIDMAN,
Pioneer in immunotherapy
CHAIRS THE SCIENTIFIC COMMITTEE OF OSE PHARMA**



The arrival of Professor Wolf Hervé at the Head of the Scientific Committee of OSE PHARMA is part of the plan to launch the phase III of its targeted lung cancer immunotherapy product.

Paris, France, November 12th 2013, OSE Pharma SA, dedicated to severe and orphan lung diseases announces today that **Professor Wolf Hervé Fridman**, pioneer in immunotherapy, has accepted the chair of its Scientific Committee dedicated to the immunotherapy.

The targeted immunotherapy (OSE2101) is developed for patients with advanced lung cancer (Non-Small Cell Lung Cancer –NSCLC) and the phase 3 is in preparation. OSE 2101 is activating the T cytotoxic lymphocytes enabling them to kill the tumor cells expressing the tumor antigens. This major innovative immune therapy is presenting a new hope for cancer patients.

Professor Wolf Hervé Fridman pioneer in Immunotherapy, will chair the scientific committee of OSE Pharma. Presently Director of Cordeliers Research Center (INSERM), University Paris Descartes, he was the Head of the Immunology unit at European Georges Pompidou Hospital, Paris, France. Professor Fridman received the « William B. Coley Award » in 2010 for its work on the major role of the immune response, in particular T lymphocytes, in the defense against cancers. The Scientific committee of OSE Pharma chaired by Professor Fridman will be composed of international experts and opinion leaders who will bring an active support to the innovative products currently developed.

“We are proud to welcome Professor Fridman as our scientific chairman. He will enrich the scientific vision of the company” declares Dominique Costantini, M.D., CEO of the company.

« The scientific Committee chaired by Wolf Hervé Fridman, consisted of several personalities and opinion leaders of international fame, will bring an active support for the innovations » states Emile Loria, M.D., Chairman of the Board for OSE Pharma.

Contacts presse

OSE Pharma SA

Dominique Costantini, CEO

dominique.costantini@osepharma.com

Mob +33 6 13 20 77 49

H&B Communication

Florence Portejoie

+33 1 58 18 32 58 / +33 6 88 84 81 74

f.portejoie@hbcommunication.fr

Anne Hardy

+33 1 58 18 32 51 / +33 6 13 56 23 96

a.hardy@hbcommunication.fr

COMPANY PROFILE: Orphan synergy Europe, OSE Pharma, an innovative clinical late stage (Phase III status) biopharmaceutical company established in Paris Hospital Cochin France. The company was founded in 2012 by Emile Loria and Dominique Costantini both experienced Biotech entrepreneurs. OSE Pharma has in-licensed its targeted cancer immunotherapy product OSE2101 for the management of international development and has retained European commercial rights. The company is focused on targeting severe and orphan pulmonary diseases. This medico-economic model is based on protection and acceleration of development for drugs significantly improving treatment options for patients with unmet medical needs. OSE lead product OSE2101 has completed a Phase II clinical trial in late-stage non-small cell lung cancer HLA A2 positive patients. This HLA A2 biomarker is expressed in 45% of this population and is considered as a poor prognosis factor in various cancers including the NSCLC. The 10 epitopes combined are providing T cytotoxic responses (able to kill cells) of the tumor cells expressing the tumor antigens. The 5 Tumor associated antigens targeted - TAA (HER2/neu; P53; CEA; MAGE2; MAGE3) have been selected as their presence is linked to the poor prognosis and severity of various cancers. Two clinical phase I/II results in colon cancer and in NSCLC were performed to define the tolerance, the level of response (>90%) and the scheme of administration (subcutaneous injection every 3 weeks for 6 injections then every 3 months).

OSE 2101 cancer immune therapy could potentially be applied to other cancer indications.

The company is preparing a separate clinical project in Cystic Fibrosis, an orphan genetic disorder with progressive lung damage, reprofiling a molecule with new anti-inflammatory properties. This molecule safety profile is already established allowing the immediate design of a clinical phase II Proof of concept program.